The more than 136 000 Cuban victims of rheumatoid arthritis, chronic disease that strikes bones and cartilage, affecting mainly female population, will be benefitted with the production and massive application of the biotech-product Jusvinza(CIGB-814/258), the glucagon-like used in the treatment of rheumatoid arthritis and hyper inflammation. 

The molecule, obtained and patented by the CIGB has already displayed the benefits it brings in the treatment of Covid-19 patients and has the opportunity of getting a Clinical Registration conditioned to phase III execution of Clinical Trials granted by the Regulatory Authority of Medicine, Equipment and Medical Devices (CEDMED).

Further information: CEDMED autoriza el medicamento Jusvinza para el uso de emergencia en el tratamiento de la Covid-19.

https://www.gramma.cu/cuba-covid-19/2020-06-19/cedme3d-autoriza-jusvinza-para-uso-de-emergencia -en-el-tratamiento-a-la-covid-19

The information was made public by PhD inn Sciences María del Carmen Domínguez, at the meeting held last Tuesday by the Prime Minister of de Central Committee of the Communist Party of Cuba, Miguel Diaz-Canel Bermúdez with scientists and experts involved in in the scientific and technological innovation activities for the fight against coronavirus, to which Manuel Marrero Cruz, member of the political Bureau and Prime Minister, also attended.

The researcher announced that this year the clinical trial phase II of Jusvinza could begin, during which is it foreseen to treat 66 000, more than the 50% of the patients reported suffering this disease in the country.

According to exchanges held with the Regulatory Authority- she explained-it is foreseen to apply a scientific assessment by the CEDMED for granting a Clinical Registration conditioned to the treatment of hyper-inflammation, and the development of controlled clinical trials and compassion studies, among others.

Rheumatoid arthritis, pointed out Dr. María del Carmen Dominguez, affects 1.2% of the Cuban population. The disease affects around the 1% of the world population; three females per male in accordance to gender parameters, and the debut of the disease is estimated to happen between the 40 and 60 years of age.

Source: Gramma